SCHEMBL69008

SCHEMBL69008

O=C(O)c1cc(-c2ccc(C(F)(F)F)cc2)[nH]n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TNIK Q9UKE5 2/20 0.48
MAPK1 P28482 2/20 0.47
MAP2K4 P45985 2/20 0.47
MAPK6 Q16659 2/20 0.47
MAPKAPK3 Q16644 1/20 0.47
MAPKAPK5 Q8IW41 1/20 0.47
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
GPR35 Q9HC97 1/20 0.44
KDR P35968 1/20 0.43
TP53 P04637 1/20 0.43
SNCA P37840 2/20 0.43
SLC6A2 P23975 1/20 0.43
P2RY14 Q15391 1/20 0.43
DAO P14920 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
IGFBP3 P17936 1/20 0.42
NOTUM Q6P988 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4695074 0.84 KMT2A (0.58) MEN1KMT2APOLBMAPTTP53
SCHEMBL8364912 0.82 KMT2A (0.54) MEN1KMT2ATNIKMAPK1POLB
SCHEMBL70800 0.82 RAB9A (0.55) MEN1KMT2APOLBMAPTDAO
SCHEMBL70360 0.82 CA12 (0.53) MEN1KMT2ATNIKPOLBMAPT
SCHEMBL27653213 0.81 AURKA (0.51) MEN1KMT2APOLBMAPTNOTUM
SCHEMBL3519352 0.80 MEN1 (0.55) MEN1KMT2APOLBMAPTDAO
SCHEMBL29019950 0.80 MEN1 (0.51) MEN1KMT2AMAPK1MAP2K4MAPK6
SCHEMBL69492 0.80 MEN1 (0.58) MEN1KMT2APOLBMAPTTP53
SCHEMBL5023368 0.79 KMT2A (0.57) MEN1KMT2ATNIKPOLBMAPT
SCHEMBL1413865 0.79 ALPL (0.53) MEN1KMT2ATNIKPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US claimed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO claimed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US claimed
US-10973810-B2 Methods for the treatment of neurological disorders YUMANITY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
EP-3566055-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Yumanity Therapeutics, Inc. (US) 2019-11-13 EP disclosed
US-20180193325-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2018-07-12 US disclosed
WO-2018129403-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS (US) 2018-07-12 WO disclosed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
CN-102036558-A Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors FOREST LAB HOLDINGS LTD 2011-04-27 CN disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
EP-2167472-A2 1-BENZYLPYRAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-03-31 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed
CN-100467463-C Pyrazolylindolyl derivatives as PPAR activators HOFFMANN LA ROCHE (CH) 2009-03-11 CN disclosed
WO-2009004171-A2 1-BENZYLPYRAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-01-08 WO disclosed
CN-1930150-A Pyrazolyl indolyl derivatives as PPAR activators HOFFMANN LA ROCHE (CH) 2007-03-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10973810-B2 Methods for the treatment of neurological disorders NLN, CLN6, OTC MEN1 2780/4885KMT2A 2541/4885TNIK 3378/4885
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 MEN1 4884/4885KMT2A 1352/4885TNIK 1573/4885
US-20180193325-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NLN, CLN6, OTC MEN1 2780/4885KMT2A 2541/4885TNIK 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.